Central nervous system agents and erectile dysfunction.
Kumar. Rajeev R; Nehra. Ajay A
Key Findings
- Nasal apomorphine and bremelanotide show the most promise among CNS agents for ED
- These agents could be useful for men who fail PDE5 inhibitors or can’t take them due to side effects or nitrate use
- Current evidence on efficacy and safety is still insufficient for widespread adoption
Practical Outcomes
- If you’re looking for an alternative to Viagra, bremelanotide (pt‑141) is a candidate to watch, but it’s not yet approved and more research is needed before you can safely use it in a self‑experiment.
Summary
The paper reviews brain‑acting drugs like nasal bremelanotide (pt‑141) that might help men who can’t use Viagra or similar pills, but the data are still limited and they aren’t approved yet.
Abstract
Several centrally acting agents have shown potential to improve erectile function in men with ED. They still lack adequate data in efficacy and tolerability. Nasal formulations of apomorphine and bremelanotide seem to be the most likely candidates for future approval. They may play a role, specifically in men who fail phosphodiesterase 5 (PDE5) therapy, are unable to take PDE5 inhibitors because of side effects, or are on nitrate therapy. This article reviews the centrally acting agents and the data on their efficacy.
Study Information
pubmed
2011
2011-05-01T00:00:00.000Z
10.1016/j.ucl.2011.03.006
4
57